A Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

Phase 2CompletedNCT01004016

Kissei Pharmaceutical Co., Ltd.20 enrolled

Overview

To evaluate the efficacy and safety of KPS-0373 in patients with SCD.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Spinocerebellar Degeneration

Interventions

KPS-0373DRUG

PlaceboDRUG

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Japanese SCD patients with mild to moderate ataxia Exclusion Criteria: * Patients with secondary ataxia * Patients with clinically significant hepatic, renal, or cardiovascular dysfunction

Locations (1)

Japan

Japan, Japan

Outcomes

Primary Outcomes

Scale for Assessment and Rating of Ataxia (SARA)

Time frame: 4 weeks + 12 weeks

Upper and lower extremity function

Time frame: 4 weeks + 12 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.